05:02 PM EST, 12/26/2024 (MT Newswires) -- Viracta Therapeutics ( VIRX ) said late Thursday its board has launched a process to explore options, including a potential merger, sale or licensing deal.

While the board reviews Viracta's options, the company said it has decided to close its phase 2 trial of Nana-val for the treatment of relapsed/refractory EBV+ lymphomas to maximize its cash runway.

The closure of the trial is not due to any new safety finding, the company added.

Viracta shares dropped almost 16% in recent after-hours activity.

Price: 0.20, Change: -0.04, Percent Change: -15.57